mp.weixin.qq.com·· 10 hours agoPickScore96
Phase III VOLGA: Perioperative Durvalumab Plus Neoadjuvant Enfortumab Vedotin Cuts Muscle-Invasive Bladder Cancer Recurrence Risk 49% and Death Risk 42%
In brief
Phase III VOLGA data show perioperative durvalumab plus neoadjuant enfortumab vedotin significantly improved EFS and OS in muscle-invasive bladder cancer. In a prespecified interim analysis of patients ineligible for or refusing cisplatin-based chemotherapy, the combination (n=233) versus control (n=229) showed an EFS HR of 0.51 (95% CI 0.38-0.67; p<0.0001) and an OS HR of 0.58 (95% CI 0.40-0.83; p=0.0027).
Why it matters
The material gives EFS and OS hazard ratios with two-year survival rates, standard-of-care controls and adverse event data for comparing benefit and safety.
Source: mp.weixin.qq.com · mp.weixin.qq.com